Revolution Medicines (RVMD) Research & Development (2019 - 2026)
Revolution Medicines (RVMD) posted quarterly Research & Development of $344.0 million for Q1 2026, up 67.18% year-over-year from $205.7 million in Q1 2025, and up 16.62% quarter-over-quarter from $294.9 million in Q4 2025.
Revolution Medicines (RVMD) Research & Development (2019 - 2026) Analysis & Trends
Revolution Medicines' Research & Development history runs 8 years deep, the most recent figure standing at $344.0 million for Q1 2026.
- In Q1 2026, Research & Development rose 67.18% year-over-year to $344.0 million; the TTM figure through Mar 2026 stood at $1.1 billion (up 65.39% YoY), while the FY2025 annual figure was $987.3 million, up 66.72% from the prior year.
- Research & Development for Q1 2026 stood at $344.0 million, up from $294.9 million in the prior quarter.
- The five-year high for Research & Development was $344.0 million in Q1 2026, with the low at $56.5 million in Q1 2022.
- The 5-year median for Research & Development is $134.9 million (2024), against an average of $153.0 million.
- Peak annual rise in Research & Development reached 124.54% in 2023, while the deepest fall reached 22.05% in 2023.
- Revolution Medicines' Research & Development stood at $66.1 million in 2022, then soared by 124.54% to $148.5 million in 2023, then gained by 26.68% to $188.1 million in 2024, then surged by 56.8% to $294.9 million in 2025, then climbed by 16.62% to $344.0 million in 2026.
- Business Quant data shows RVMD's Research & Development at $344.0 million in Q1 2026, $294.9 million in Q4 2025, and $262.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 202.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 394.92 Mn |
| Mar 31, 2026 | 343.97 Mn |
| Dec 31, 2025 | 294.94 Mn |
| Sep 30, 2025 | 262.51 Mn |
| Jun 30, 2025 | 224.13 Mn |
| Mar 31, 2025 | 205.75 Mn |
| Dec 31, 2024 | 188.10 Mn |
| Sep 30, 2024 | 151.75 Mn |
| Jun 30, 2024 | 134.93 Mn |
| Mar 31, 2024 | 118.02 Mn |
| Dec 31, 2023 | 148.48 Mn |
| Sep 30, 2023 | 107.74 Mn |
| Jun 30, 2023 | 97.98 Mn |
| Mar 31, 2023 | 68.95 Mn |
| Dec 31, 2022 | 66.13 Mn |
| Sep 30, 2022 | 69.46 Mn |
| Jun 30, 2022 | 61.00 Mn |
| Mar 31, 2022 | 56.49 Mn |
| Dec 31, 2021 | 53.68 Mn |
| Sep 30, 2021 | 46.47 Mn |